Overview
- Ro launched the campaign on Oct. 1, 2026, with Megan Fox starring as the human embodiment of Ro Sparks in a cheeky TV spot and planned New York out‑of‑home activations.
- The company presents Ro Sparks as a prescription, sublingual two‑in‑one treatment combining sildenafil and tadalafil that dissolves under the tongue for faster absorption and can last up to 36 hours.
- Ro positioned Fox as a long‑term ambassador who will appear in ads for up to one to two years and said using a woman was intentional to prompt men and partners to talk about ED.
- Coverage flags a regulatory nuance: both active ingredients are FDA‑approved but at least one report says the compounded Ro Sparks formulation itself is not FDA‑approved, a point consumers and prescribers should note.
- The campaign continues a trend of telehealth brands using bold, celebrity-led DTC marketing to scale prescriptions and could increase patient demand while drawing closer regulatory scrutiny of compounded products.